| Date | Title | Description |
| 05.09.2024 | Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial | Dana-Farber Cancer Institute in Boston, MA and Montefiore Medical Center in New York, NY Join Clinical Trial
NEW YORK, Sept. 5, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today ... |
| 15.08.2024 | Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer Therapeutic | Aronnax to Determine the Maximum-Tolerated Dose (MTD) Post Intravenous Injection Followed by a Dose Range-Finding Phase of Hoth's Orphan Drug HT-KIT
NEW YORK, Aug. 15, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-f... |
| 16.07.2024 | Hoth Therapeutics Expands Clinical Trial for Cancer Patients | Three New Sites Join HT-001 Trial, GW University Hospital, UC Irvine and Northwell Health
NEW YORK, July 16, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it h... |
| 10.06.2024 | Hoth Therapeutics Announces Joint Development Agreement with Wise Systems International SRL to Utilize Artificial Intelligence for Drug Discovery | Nvidia BioNeMo generative AI platform will be used to accelerate the training of models on proprietary data
NEW YORK, June 10, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today a... |
| 27.03.2024 | Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds | NEW YORK, March 27, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants t... |
| 30.12.2022 | Hoth Therapeutics Announces $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules | NEW YORK, Dec. 29, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. HOTH, a patient-focused biopharmaceutical company, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 2,000,000 shares... |
| 09.02.2022 | Hoth Therapeutics Announces the selection of NUVISAN for Manufacturing HT-001 Drug Batches for CLEER-001 Clinical Study for Cancer Patients | NEW YORK, Feb. 9, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has signed an agreement with NUVISAN, a European CRO/CDMO with topical manufacturing capabilities... |
| 07.02.2022 | Hoth Therapeutics Announces Presentation of the HT-ALZ Proof-of-Concept Alzheimer's Disease Preclinical Data at the 2022 Alzheimer's Association International Conference | NEW YORK, Feb. 7, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced an abstract submission to present the preclinical Alzheimer's disease mouse model data of HT-ALZ at ... |
| 31.01.2022 | Hoth Therapeutics Announces the Appointment of John Cirrito, PhD and Carla Yuede, PhD to Oversee Alzheimer's Therapeutic Program as Part of Hoth Scientific Advisory Board | NEW YORK, Jan. 31, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the addition of John Cirrito, PhD and Carla Yuede, PhD to the Company's Scientific Advisory Board.
... |
| 04.01.2022 | Hoth Therapeutics : Announces HT-ALZ Therapeutic Shows Positive Results - Reduce Amyloid β in Alzheimer's Disease - Form 8-K | Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Positive Results - Reduce Amyloid β in Alzheimer's Disease
Significant decrease in Aβ seen in an Alzheimer's disease mouse model after acute treatment with HT-ALZ, supporting that HT-ALZ ... |
| 04.01.2022 | Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Positive Results - Reduce Amyloid β in Alzheimer's Disease | NEW YORK, Jan. 4, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced proof-of-concept data generated using an Alzheimer's disease mouse model, supporting the therapeutic... |
| 21.12.2021 | Hoth Therapeutics Announces Submission of Orphan Drug Designation Request for HT-KIT to Treat Mastocytosis | NEW YORK, Dec. 21, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a patient-focused clinical-stage biopharmaceutical company, announced it submitted an Orphan Drug Designation Request to the US Food and Drug Administration (FDA... |
| 08.12.2021 | Hoth Therapeutics Licenses Lupus Therapeutic Back to Zylö Therapeutics | NEW YORK, Dec. 8, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs, is pleased to announce that it has entered int... |
| 08.12.2021 | Systemic Lupus Erythematosus Treatment Market Projected To Reach $3.56 Billion By 2027 | PALM BEACH, Fla., Dec. 8, 2021 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - Systemic Lupus Erythematosus is also known as lupus. It is an autoimmune disease that affects all parts of your body. The reason for the occurrence of a... |
| 30.11.2021 | Hoth Therapeutics' Enrollment and Dosing in Second Cohort in Phase 1b Human Trial for Atopic Dermatitis Under Way | NEW YORK, Nov. 30, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs, is pleased to announce that enrollment and do... |
| 16.11.2021 | Hoth Therapeutics Announces a Sponsored Research Agreement to Further Develop Novel mRNA Cancer Therapeutic HT-KIT | NEW YORK, Nov. 16, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has signed a Sponsored Research Agreement with North Carolina State University ("NC St... |
| 16.11.2021 | Hoth Therapeutics Announces a Sponsored Research Agreement to Further Develop Novel mRNA Cancer Therapeutic HT-KIT | NEW YORK, Nov. 16, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has signed a Sponsored Research Agreement with North Carolina State University ("NC St... |
| 16.11.2021 | Global Cancer Therapy Market Expected to Reach $268 Billion In 2026, With A CAGR Of 9.15% | PALM BEACH, Fla., Nov. 16, 2021 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - The COVID-19 pandemic has affected the healthcare systems globally and also has a significant impact on the cancer therapy market. As per the article p... |
| 08.11.2021 | Hoth Therapeutics Inks API and Drug Product Contracts with WuXi STA to Advance Manufacturing of HT-KIT Cancer Therapeutic | NEW YORK, Nov. 8, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc., (NASDAQ: HOTH) a patient focused biopharmaceutical company, announced today that it has entered into two contracts with STA Pharmaceutical, a subsidiary of WuXi AppTec (WuXi ST... |
| 19.10.2021 | Hoth Therapeutics : Extends Partnership Agreement with REPROCELL | NEW YORK, Oct. 19, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) has extended its partnership agreement with REPROCELL to assess the effect of the HT-003 therapeutic platform in inflammatory bowel disease (IBD). Fresh explants... |
| 19.10.2021 | Hoth Therapeutics Extends Partnership Agreement with REPROCELL | NEW YORK, Oct. 19, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) has extended its partnership agreement with REPROCELL to assess the effect of the HT-003 therapeutic platform in inflammatory bowel disease (IBD). Fresh explants... |
| 12.10.2021 | Global Atopic Dermatitis Treatment Market Size Is Projected To Be Worth US$21.80 Billion By 2026 | FinancialNewsMedia.com News Commentary
PALM BEACH, Fla., Oct. 12, 2021 /PRNewswire/ -- Atopic Dermatitis is an inflammatory skin disease, and the degree of its severity varies from patient to patient. It usually begins in childhood and is m... |
| 12.10.2021 | Global Atopic Dermatitis Treatment Market Size Is Projected To Be Worth US$21.80 Billion By 2026 | PALM BEACH, Fla., Oct. 12, 2021 /PRNewswire/ -- Atopic Dermatitis is an inflammatory skin disease, and the degree of its severity varies from patient to patient. It usually begins in childhood and is mostly confined to the flexural surfaces... |
| 12.10.2021 | Hoth Therapeutics : Receives Approval to Commence Cohort 2 in Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis Patients | NEW YORK, Oct. 12, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that is has received Human Research Ethics Committee (HREC) clearance to commence cohort 2 of the Phase 1b clinical... |
| 21.09.2021 | Hoth Therapeutics : Submits to Ethics Committee for Approval to Initiate Patient Cohort 2 in BioLexa Clinical Trial | NEW YORK, Sept. 21, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that a Safety Review Committee (SRC) has reviewed the safety data from the first cohort of healthy... |
| 08.09.2021 | Hoth Therapeutics Announces Positive Phase 1b Results for Completed First Cohort of Patient Trial of BioLexa | |
| 08.09.2021 | Hoth Therapeutics : Announces Positive Phase 1b Results for Completed First Cohort of Patient Trial of BioLexa | NEW YORK, Sept. 8, 2021 /PRNewswire/ -- Today, Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, announced the completed safety results in Cohort 1 of its first in human clinical trial of the proprietary B... |
| 11.08.2021 | Hoth Therapeutics' : mRNA 'Frameshifting' Therapy HT-KIT for Mast Cell Cancers Reduces Size, Spread - Research Published in Molecular Therapy | NEW YORK, Aug. 11, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today highlights recent findings from North Carolina State University, that its new treatment for mast cell cancers... |
| 11.08.2021 | Hoth Therapeutics' mRNA 'Frameshifting' Therapy HT-KIT for Mast Cell Cancers Reduces Size, Spread - Research Published in Molecular Therapy | |
| 02.08.2021 | Hoth Therapeutics : Initiates Preclinical Study of HT-ALZ for Alzheimer's Disease | NEW YORK, Aug. 2, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it has initiated its preclinical study utilizing Hoth's HT-ALZ in an animal model.
The goal of ... |
| 02.08.2021 | Hoth Therapeutics Initiates Preclinical Study of HT-ALZ for Alzheimer's Disease | |
| 13.07.2021 | Hoth Therapeutics Announces Positive Confirmatory Results from In Vivo Model of HT-003 Assets as Potential Treatment Against Acne | |
| 13.07.2021 | Hoth Therapeutics : Announces Positive Confirmatory Results from In Vivo Model of HT-003 Assets as Potential Treatment Against Acne | NEW YORK, July 13, 2021 /PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that its HT-003 group of assets has yielded positive results in an in vivo acne therapeutic model. Th... |
| 28.06.2021 | Hoth Therapeutics : Announces Positive Safety Results from AD001 Cohort 1 of Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis | NEW YORK, June 28, 2021 /PRNewswire/ -- Today, Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, announced the safety results in Cohort 1 of its first in human clinical trial of the proprietary BioLexa pla... |
| 28.06.2021 | Hoth Therapeutics Announces Positive Safety Results from AD001 Cohort 1 of Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis | |
| 07.06.2021 | Hoth Therapeutics Announces Sponsored Research Agreement with Washington University for Novel Alzheimer's Therapeutic HT-ALZ | |
| 07.06.2021 | HOTH THERAPEUTICS, INC.
Hoth Therapeutics : Announces Sponsored Research Agreement with Washington University for Novel Alzheimer's Therapeutic HT-ALZ | NEW YORK, June 7, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into a Sponsored Research Agreement with Washington University in St. Louis to s... |
| 03.06.2021 | Hoth Therapeutics Shares Positive Preclinical Results of Novel HT-KIT Therapeutic | |
| 03.06.2021 | HOTH THERAPEUTICS, INC.
Hoth Therapeutics : Shares Positive Preclinical Results of Novel HT-KIT Therapeutic | NEW YORK, June 3, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it will share positive results from a preclinical trial during its shareholder presentation, re... |
| 01.06.2021 | HOTH THERAPEUTICS, INC.
Hoth Therapeutics : Plans Shareholder Presentation on HT-KIT Therapeutic's Preclinical Results for Rare Cancers | NEW YORK, June 1, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today plans to host a virtual information session on its pipeline product, HT-KIT, a new molecular entity ... |
| 01.06.2021 | Hoth Therapeutics Plans Shareholder Presentation on HT-KIT Therapeutic's Preclinical Results for Rare Cancers | |
| 24.05.2021 | Hoth Therapeutics Announces Participation at the American Society of Clinical Oncology (ASCO) Annual Meeting | |
| 13.05.2021 | Hoth Therapeutics Provides Shareholder Update on Novel Endocannabinoid Therapeutic for Cutaneous Lupus Erythematosus | |
| 13.05.2021 | HOTH THERAPEUTICS, INC.
Hoth Therapeutics : Provides Shareholder Update on Novel Endocannabinoid Therapeutic for Cutaneous Lupus Erythematosus | NEW YORK, May 13, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today it plans to host a virtual information session on its pipeline product, HT-005 Z-Pods™, a novel endo... |
| 05.05.2021 | HOTH THERAPEUTICS, INC.
Hoth Therapeutics : and Virginia Commonwealth University Expand Research Agreement for COVID-19 Therapeutic | NEW YORK, May 5, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has expanded its sponsored research agreement with Virginia Commonwealth University (VCU) for a potential COVID-19... |
| 05.05.2021 | Hoth Therapeutics and Virginia Commonwealth University Expand Research Agreement for COVID-19 Therapeutic | |
| 05.05.2021 | Hoth Therapeutics and Virginia Commonwealth University Expand Research Agreement for COVID-19 Therapeutic | NEW YORK, May 5, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has expanded its sponsored research agreement with Virginia Commonwealth University (VCU) for a potential COVID-19... |
| 03.05.2021 | HOTH THERAPEUTICS, INC.
Hoth Therapeutics : Announces Development of HT-KIT to Treat Multiple Orphan Diseases, Including Rare Cancers | NEW YORK, May 3, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a patient-focused clinical-stage biopharmaceutical company, announced it intends to pursue development of its HT-KIT mRNA Frame Shifting Therapeutic for multiple o... |
| 03.05.2021 | Hoth Therapeutics Announces Development of HT-KIT to Treat Multiple Orphan Diseases, Including Rare Cancers | |
| 22.04.2021 | Hoth Therapeutics' First in Human Clinical Trial for the Treatment of Atopic Dermatitis with BioLexa is Underway | |
| 22.04.2021 | HOTH THERAPEUTICS, INC.
Hoth Therapeutics' : First in Human Clinical Trial for the Treatment of Atopic Dermatitis with BioLexa is Underway | NEW YORK, April 22, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs, is pleased to announce the start of its Firs... |
| 20.04.2021 | Hoth Therapeutics Announces its mRNA Frame Shifting Therapeutic Significantly Inhibits Tumor Growth in Mast Cell-Derived Cancers | |
| 20.04.2021 | HOTH THERAPEUTICS, INC.
Hoth Therapeutics : Announces its mRNA Frame Shifting Therapeutic Significantly Inhibits Tumor Growth in Mast Cell-Derived Cancers | NEW YORK, April 20, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, announced that its novel anti-cancer therapeutic exhibited highly positive results in humanized mas... |
| 12.04.2021 | Hoth Therapeutics Completes HT-001 Formulation Development for Upcoming Cancer Patient Clinical Trial | |
| 12.04.2021 | HOTH THERAPEUTICS, INC.
Hoth Therapeutics : Completes HT-001 Formulation Development for Upcoming Cancer Patient Clinical Trial | NEW YORK, April 12, 2021 /PRNewswire/ -- Today, Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, together with its manufacturing partner, has successfully completed the formulation for HT-001, a treatment... |
| 07.04.2021 | HOTH THERAPEUTICS, INC.
Hoth Therapeutics : Engages Worldwide Clinical Trials as Contract Research Organization for Phase 2a HT-001 Clinical Trial for Cancer Patients | NEW YORK - Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, announced that it has engaged Worldwide Clinical Trials ('Worldwide'), a full-service Contract Research Organization ('CRO') for its upcoming Ph... |
| 06.04.2021 | Hoth Therapeutics Engages Worldwide Clinical Trials as Contract Research Organization for Phase 2a HT-001 Clinical Trial for Cancer Patients | |
| 05.04.2021 | Hoth Therapeutics, Inc. Announces Notice of Allowance for a New Patent Application Related to A Method for Inhibiting Formation of a Biofilm | |
| 05.04.2021 | HOTH THERAPEUTICS, INC.
Hoth Therapeutics, Inc. : Announces Notice of Allowance for a New Patent Application Related to A Method for Inhibiting Formation of a Biofilm | NEW YORK, April 5, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced that the Brazilian Patent Office has issued a notice of allowance for a patent appli... |
| 23.03.2021 | Hoth Therapeutics Announces Positive Preclinical Results for Novel COVID-19 Therapeutic | |
| 19.03.2021 | Hoth Therapeutics CEO, Robb Knie, Featured on the RedChip Money Report on Bloomberg TV this Saturday, March 20th | |
| 17.03.2021 | Hoth Therapeutics Partners with University of Cincinnati to Perform Critical Studies for Streamlined Development of Novel Antibiotic HT-006 | |
| 11.03.2021 | Hoth Therapeutics Executes Agreement to Assess the Effect of HT-003 Therapeutic Platform on Ulcerative Colitis and Crohn's Disease | |
| 10.03.2021 | Hoth Therapeutics Completes Closing of Previously Announced $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules | |
| 08.03.2021 | Hoth Therapeutics Announces $15 Million Private Placement Priced At-the-Market Under Nasdaq Rules | NEW YORK, March 8, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused clinical stage biopharmaceutical company, today announced that it has entered into a definitive agreement with certain institutional and accre... |
| 03.03.2021 | Hoth Therapeutics Provides Update on Novel Peptide COVID-19 Therapeutic HT-002 Preclinical Studies | |
| 01.03.2021 | Hoth Therapeutics Completes Site Recruitment for Cohort 1 of First in Human Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis | |
| 26.02.2021 | Hoth Therapeutics Expands License Agreement to Include Innovative Cancer and Anaphylactic Treatment | |
| 26.02.2021 | Hoth Therapeutics Expands License Agreement to Include Innovative Cancer and Anaphylactic Treatment | NEW YORK, Feb. 26, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has expanded its licensing agreement from North Carolina State University ("NC State") to include the ... |
| 25.02.2021 | Hoth Therapeutics Retains RedChip to Increase Investor Awareness | |
| 24.02.2021 | Hoth Therapeutics Expands Intellectual Property Portfolio with Novel Alzheimer's Treatment | |
| 23.02.2021 | Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Proposed Development of HT-001 For Cancer Patients | |
| 18.02.2021 | Hoth Therapeutics' HT-003 Shows Anti-inflammatory Benefits, Hoth to Expand Drug Development to Include Treatment of Inflammatory Bowel Diseases (IBDs) | |
| 18.02.2021 | Hoth Therapeutics' HT-003 Shows Anti-inflammatory Benefits, Hoth to Expand Drug Development to Include Treatment of Inflammatory Bowel Diseases (IBDs) | NEW YORK, Feb. 18, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it intends to expand the development of the HT-003 active pharmaceutical ingredient (API) to pursue a new indi... |
| 17.02.2021 | Hoth Therapeutics to Present at the Diamond Equity Research Emerging Growth Invitational 2021 Virtual Conference | NEW YORK, Feb. 17, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it will be presenting at the upcoming the Diamond Equity Research Growth Invitational virtual investor confere... |
| 17.02.2021 | Hoth Therapeutics to Present at the Diamond Equity Research Emerging Growth Invitational 2021 Virtual Conference | |
| 10.02.2021 | Hoth Therapeutics Scientific Advisory Board Member, Michael Peters, Ph.D., Publishes Whitepaper Regarding COVID-19 SARS-CoV-2 in bioRxiv | |
| 10.02.2021 | Hoth Therapeutics Scientific Advisory Board Member, Michael Peters, Ph.D., Publishes Whitepaper Regarding COVID-19 SARS-CoV-2 in bioRxiv | NEW YORK, Feb. 10, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Scientific Advisory Board member, Michael Peter, Ph.D., published a whitepaper in bioRxiv regarding COVID-19 S... |
| 08.02.2021 | Hoth Therapeutics Partners with Camargo Pharmaceutical Services for the HT-001 IND, a Treatment for Cancer Patients | |
| 02.02.2021 | Hoth Therapeutics Provides Operational Update on Novel Therapeutic Pipeline | |
| 28.01.2021 | Hoth Therapeutics Expands Research Collaboration Agreement with Weill Cornell Medicine to Continue the Advancement of HT-003 for Acne Treatment Research | |
| 27.01.2021 | Hoth Therapeutics Announces the Appointment of Mario E. Lacouture, M.D. to Oversee Dermatology Therapeutic Program for Cancer Patients as Part of Hoth Scientific Advisory Board | |
| 20.01.2021 | Hoth Therapeutics Announces Positive Initial Mechanism of Action Data for HT-003 In Pursuit for Acne Treatment Indication | |
| 13.01.2021 | FDA Grants Hoth Therapeutics Pre-IND Meeting Regarding Proposed Drug Development Plan for HT-001 Treatment for Cancer Patients | |
| 11.01.2021 | Hoth Therapeutics to Initiate IND Enabling Studies of HT-001 Treatment for Cancer Patients | |
| 05.01.2021 | Hoth Therapeutics Announces Private Placement of Equity Priced At-The-Market Under Nasdaq Rules | |
| 04.01.2021 | Hoth Therapeutics Announces Licensing Agreement and Collaboration with U.S. Army Medical Research and Development Command (USAMRDC) for Treating Multi-Drug Resistant Bacterial Lung Infections | |
| 31.12.2020 | Hoth Therapeutics Announces Production of HT-001 for Cancer Treatment | |
| 23.12.2020 | Hoth Therapeutics Submits Request for a Pre-Investigational New Drug (Pre-IND) Meeting for HT-001, Treatment for Cancer Patients | |
| 21.12.2020 | Endocannabinoid Pathway Targeted Drug Demonstrates Proof-of-Concept Efficacy in a Cutaneous Lupus Erythematosus Mouse Model | |
| 10.12.2020 | Hoth Therapeutics Receives Approval to Commence Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis in Humans | |
| 03.11.2020 | Hoth Therapeutics Announces Positive, Statistically Significant Proof-of-Concept Preclinical Data on its Therapeutic for Cutaneous Lupus Erythematosus (CLE), a Chronic Autoimmune Skin Disease | |
| 02.11.2020 | Hoth Therapeutics Provides Update for Novel COVID-19 Therapeutic, On-the-Go SARS-CoV-2 Testing Device, and Vaccine | |
| 20.10.2020 | Hoth Therapeutics Announces USPTO Grant of Patent for Targeted 13-Cis-RAMBA Retinamides for Development as a Novel Cancer Therapeutic | |
| 24.09.2020 | Hoth Therapeutics Announces its HT-003 Shows Positive Initial Data Inhibiting Toll-like Receptor 2 (TLR2) | |
| 21.09.2020 | Hoth Therapeutics Enters into Sponsored Research Agreement for On-the-Go COVID-19 Testing Device | |
| 01.09.2020 | Hoth Therapeutics' Chief Scientific Officer, Dr. Stefanie Johns, to Appear on One America News Network on Tuesday, September 1, 2020 | |
| 01.04.2020 | Coronavirus Business Tracker: How The Private Sector Is Fighting The Covid-19 Pandemic | Alain Mérieux, founder of BioMérieux.AFP via Getty Images |
| 23.02.2018 | Term Sheet — Friday, February 23 | THE ‘PAYTRIARCHY’
Happy Friday, Term Sheet readers.
Paid Content You can't secure what you can't see From ExtraHop
Weiss, who has been called the “millennials’ Estée Lauder,” didn’t have such an easy time raising her first round of capital ... |
| 22.02.2018 | Hoth Therapeutics Completes $3M Series A Financing | Hoth Therapeutics Inc., a Nevada based development stage biopharmaceutical company, also known as eczema, completed a $3m Series A financing.
The backers remained undisclosed.
The company intends to use the funds to advance its BioLexa Plat... |
